Since motor neuron degeneration is the primary manifestation observed in SMA, our finding that the Bap1/SMN pathway is required in non-neuronal FAPs for the maturation and maintenance of the neuromuscular system sheds light on SMA pathogenesis and provides an additional therapeutic strategy to treat SMA. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.